title: A clinicopathologic study of chronic non-A, non-B (type C) hepatitis in Taiwan: comparison between posttransfusion and sporadic patients.
abstract: To elucidate the clinicopathological course and the role of hepatitis C virus in posttransfusion and sporadic chronic non-A, non-B hepatitis in Taiwan, we retrospectively studied 85 histologically confirmed patients with long-term follow up. Antibodies against hepatitis C virus (anti-HCV) by a second-generation assay were positive in 81% of the patients: 88% in the posttransfusion group and 76% in the sporadic group. Clinical manifestations were generally mild, and were noted in only half of the patients. During follow up, 33% (28 of 85 patients) had episodes of acute exacerbation of chronic liver disease and 24% (20 of 85) had normalized liver tests. Patients with normalized liver tests were usually anti-HCV negative (55% vs. 8%, p < 0.001). In 34 patients who had had blood transfusions, initial liver biopsies revealed chronic active hepatitis in 41%, active cirrhosis in 6%, and inactive cirrhosis in 9%. Follow-up biopsies in eight patients in this group showed histological progression in three after an average of 40.6 months. In the 51 sporadically infected patients, initial work-up revealed chronic active hepatitis in 37%, active cirrhosis in 4%, and inactive cirrhosis in 14%. Among the nine who underwent repeated biopsies, only one (11%) had progression. Patients above age 40 displayed more severe histologic activity than those below 40 (p < 0.005). Three patients, all with cirrhosis, died of hepatocellular carcinoma 7 to 12 years after follow up. Further genotyping study of hepatitis C virus in 28 patients showed that type II virus was most predominant in Taiwan and histologic severity was similar among patients infected with different genotypes.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Internal Medicine, National Taiwan University College of Medicine, Taipei, Republic of China.
authors.forename: J H
authors.initials: JH
authors.lastname: Kao
authors.forename: S L
authors.initials: SL
authors.lastname: Tsai
authors.forename: P J
authors.initials: PJ
authors.lastname: Chen
authors.forename: P M
authors.initials: PM
authors.lastname: Yang
authors.forename: J C
authors.initials: JC
authors.lastname: Sheu
authors.forename: M Y
authors.initials: MY
authors.lastname: Lai
authors.forename: H C
authors.initials: HC
authors.lastname: Hsu
authors.forename: J L
authors.initials: JL
authors.lastname: Sung
authors.forename: T H
authors.initials: TH
authors.lastname: Wang
authors.forename: D S
authors.initials: DS
authors.lastname: Chen
mesh_terms: D000328:Adult; D001706:Biopsy; D005260:Female; D005838:Genotype; D016174:Hepacivirus / Q000276:immunology; D006508:Hepatitis Antibodies / Q000032:analysis; D006526:Hepatitis C / Q000453:epidemiology / Q000209:etiology* / Q000473:pathology*; D006801:Humans; D015994:Incidence; D008099:Liver / Q000473:pathology; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D012720:Severity of Illness Index; D013624:Taiwan / Q000453:epidemiology; D065227:Transfusion Reaction
chemical_list: D006508:Hepatitis Antibodies